GSK has agreed a settlement with the DoJ whereby it will pay $3 billion for failings in the methods used to market its products. The penalty is said to be the largest imposed in respect of healthcare fraud. The allegations originated with a whistleblower who was sacked by the company. For more see here.
JD VIEW—This case highlights the pitfalls of failing to deal correctly with concerns raised by a whistleblower and the need to put into practice stated company policy.
